Immunocore Holdings plc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 and 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMUNOCORE HOLDINGS PLC | |
| By: | /s/ Bahija Jallal |
| Bahija Jallal, Ph.D. | |
| Chief Executive Officer | |
| (Principal Executive Officer) |
POWER OF ATTORNEY
Each of the undersigned officers and directors of Immunocore Holdings plc, hereby constitutes and appoints Bahija Jallal and Travis Coy, their true and lawful attorney-in-fact and agent, for them and in their name, place and stead, in any and all capacities, to sign their name to any and all amendments to this Report on Form 10-K, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on February 26, 2025 on behalf of the registrant and in the capacities indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Bahija Jallal, Ph.D. | Chief Executive Officer and Director(Principal Executive Officer) | February 26, 2025 |
| Bahija Jallal, Ph.D. | ||
| /s/ Travis Coy | Chief Financial Officer(Principal Financial Officer) | February 26, 2025 |
| Travis Coy | ||
| /s/ John Goll | SVP, Finance and Chief Accounting Officer (Principal Accounting Officer) | February 26, 2025 |
| John Goll | ||
| /s/ Professor Sir John Bell | Chairman of the Board of Directors | February 26, 2025 |
| Professor Sir John Bell | ||
| /s/ Roy S. Herbst, M.D., Ph.D. | Director | February 26, 2025 |
| Roy S. Herbst, M.D., Ph.D. | ||
| /s/ Siddharth Kaul | Director | February 26, 2025 |
| Siddharth Kaul | ||
| /s/ Mr. Ranjeev Krishana | Director | February 26, 2025 |
| Mr. Ranjeev Krishana | ||
| Director | February 26, 2025 | |
| Dr. William Pao, M.D., Ph.D. | ||
| /s/ Robert Perez | Director | February 26, 2025 |
| Robert Perez | ||
| /s/ Kristine Peterson | Director | February 26, 2025 |
| Kristine Peterson | ||
| /s/ Professor Sir Peter Ratcliffe | Director | February 26, 2025 |
| Professor Sir Peter Ratcliffe | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 1147) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID 1118) | F-4 |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024, 2023 and 2022 | F-6 |
| Consolidated Statements of Shareholders’ Equity for the Years Ended December 31, 2024, 2023 and 2022 | F-7 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023 and 2022 | F-8 |
| Notes to the Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.